Jefferies Financial Group Inc. Makes New $885,000 Investment in Denali Therapeutics Inc. $DNLI

Jefferies Financial Group Inc. purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 34,425 shares of the company’s stock, valued at approximately $885,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after buying an additional 3,432 shares during the period. Goldman Sachs Group Inc. grew its position in Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after acquiring an additional 614,555 shares during the period. Empowered Funds LLC grew its position in Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after acquiring an additional 2,052 shares during the period. Woodline Partners LP grew its position in Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after acquiring an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock worth $2,681,000 after acquiring an additional 3,210 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Morgan Stanley upped their price target on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a report on Friday, August 7th. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.70% of the company’s stock.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $24.00 on Monday. The company has a market capitalization of $3.84 billion, a PE ratio of -8.45 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The firm has a 50 day moving average price of $24.62 and a 200 day moving average price of $21.72.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter last year, the business earned ($0.72) EPS. Research analysts expect that Denali Therapeutics Inc. will post -2.67 earnings per share for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.